EGFR-TKI Resistant Mutation Clinical Trials
0 recruiting
Showing 1–3 of 3 trials
Recruiting
Phase 1Phase 2
Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer Patients
Non-small Cell Lung CancerEGFR-TKI Resistant MutationEGFR Gene Mutation
China Medical University Hospital20 enrolled1 locationNCT06071013
Recruiting
Phase 2
Osimertinib Plus Dalpiciclib in Patients With EGFR-mutant, CDK4/6 Pathway Aberrant, Advanced Non-small Cell Lung Cancer Following Acquired Resistance to Third-generation EGFR TKI: a Phase II Trial
Non-small Cell Lung CancerEGFR-TKI Resistant MutationEGFR Activating Mutation+1 more
Tianjin Medical University Cancer Institute and Hospital32 enrolled1 locationNCT06363734
Recruiting
A Retrospective Study of EGFR-TKIs,Gefitinib, Erlotinib and Osimertinib in NSCLC Patients Treatment
Non-small Cell Lung Cancer (NSCLC)EGFR-TKI Resistant MutationEGFR-TKI Sensitizing Mutation+2 more
Sun Yat-sen University1,000 enrolled1 locationNCT01994057